Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

142.08 +2.29 (+1.64%)
Official Closing Price Updated: 4:10 PM EDT, Jul 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,877,273
Open 141.75
Bid (Size) 142.00 (5)
Ask (Size) 142.35 (14)
Prev. Close 139.79
Today's Range 141.63 - 143.49
52wk Range 75.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position. 
Via Talk Markets
Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study
A yearlong study at the University of Oxford suggests GLP-1 drugs could play a role in protecting brain health. 
Via Investor's Business Daily

Performance

YTD
+39.14%
+39.14%
1 Month
+0.20%
+0.20%
3 Month
+13.30%
+13.30%
6 Month
+33.17%
+33.17%
1 Year
+83.63%
+83.63%

More News

Read More
Stock Market Shifts Toward Small Caps After Tame CPI; JPMorgan, Taiwan Semi, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
Via Benzinga
3 Global Stocks Worth Buying as America Stumbles
Via InvestorPlace
Will NVO Provide Any Buying Opportunity?
Via Talk Markets
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Via Benzinga
FDA Rejects Novo Nordisk's Weekly Insulin, Requests Information Related To Manufacturing Process, Type 1 Diabetes
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Via Benzinga
Chipotle Just Did a Stock Split. History Says This Is What Might Happen Next.
Via The Motley Fool
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
Via Benzinga
Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted
Via InvestorPlace
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Via MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
Via InvestorPlace
3 Stocks With the Potential to 10X Your Money
Via InvestorPlace
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
Via The Motley Fool
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Via Benzinga
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Via Investor's Business Daily
3 Overlooked Giants-in-the-Making for Patient Investors
Via InvestorPlace
Novartis Stock Generating Improved Relative Strength
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.